Printed from Voxsanity (voxsanity.com.au) — NCT05197270 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Macular Degeneration
Phase 2 Macular Degeneration Trial, Recruiting
NCT05197270
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Main Trial
- People aged 50 or older
- People who have been diagnosed with a type of abnormal blood vessel growth in the eye (called CNV) caused by age-related macular degeneration (AMD), confirmed by a specialist reading centre
- People whose unaffected eye has a certain minimum level of vision, and whose study eye also meets specific vision level requirements (confirm exact vision levels with trial site)
- People whose study eye shows signs of fluid or thickness on a specialised eye scan (SD-OCT), confirmed by a reading centre, that requires ongoing eye injection treatment
- People whose study eye is suitable for receiving injections into the eye
- People who are able to complete vision and eye function tests and follow the study procedures
- People who are currently receiving anti-VEGF eye injections (such as ranibizumab, aflibercept, faricimab, or bevacizumab) in the study eye, and whose eye has shown a response to that treatment within the past 12 months
- People who have at least 12 months of medical records documenting their history of anti-VEGF eye injections, including dates, drug names, and doses
- People who agree to use a barrier method (such as a condom) during intercourse for 6 months after receiving the study treatment, to prevent fluid transmission; sexually active males must also agree not to father a child or donate sperm during this period
- People who provide written consent to participate
Contralateral Eye Sub-study (second eye)
- People who received the study treatment (4D-150) in their first study eye at least 6 months before the sub-study screening visit, and who meet additional biological sample criteria if they also participated in the Shedding Sub-study (confirm details with trial site)
- People whose second eye has been diagnosed with abnormal blood vessel growth (MNV) caused by AMD, identified on historical or screening eye scans and confirmed by a reading centre
- People whose second eye has received at least one anti-VEGF injection within the 6 months before screening, with that injection given at least 28 days before screening, and whose eye has shown a response to anti-VEGF treatment on historical scans confirmed by the reading centre
- People whose second eye has a vision level within a specific range on a standardised eye chart (confirm exact range with trial site)
- People whose second eye is suitable for receiving injections into the eye
- People whose previously treated first eye still has a minimum level of vision (confirm details with trial site)
- People who are able to follow the study procedures and visits, in the investigator's judgement
- People who agree to use a barrier method during intercourse for 6 months after receiving the study treatment in the second eye, and sexually active males must agree not to father a child or donate sperm during this period
- People who provide written consent to participate in the sub-study
Shedding Sub-study
- People aged 50 or older
- People diagnosed with abnormal blood vessel growth (MNV) caused by AMD, confirmed by specialised eye scans and a reading centre
- People whose study eye has a vision level within a specific range on a standardised eye chart at the time of screening (confirm exact range with trial site)
- People whose unaffected eye has a certain minimum level of vision (confirm details with trial site)
- People currently receiving anti-VEGF eye injections in the study eye, with at least one injection in the past 6 months and the last injection given at least 28 days before screening, and whose eye has shown a response to anti-VEGF treatment confirmed by the reading centre
- People whose study eye is suitable for receiving injections into the eye
- People who are able to complete vision and eye function tests and follow the study procedures, in the investigator's judgement
- People who agree to use a barrier method during intercourse for 6 months after receiving the study treatment, and sexually active males must agree not to father a child or donate sperm during this period
- People who provide written consent to participate
Who may not be able to join:
- The official criteria provided do not include a separate list of exclusion criteria — confirm any disqualifying conditions directly with the trial site
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Demi Dang, MD, 4D Molecular Therapeutics
Phone: (888) 748-8881
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
4D Molecular Therapeutics
Registry
ClinicalTrials.gov
Start date
9 December 2021
Est. completion
1 March 2027
Where this trial is recruiting
Puerto Rico
🇺🇸 United States
Primary endpoints
Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), including clinically significant changes in safety parameters
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.